Literature DB >> 15378762

Proteomic analysis distinguishes basaloid carcinoma as a distinct subtype of nonsmall cell lung carcinoma.

Long Shan Li1, Hyunki Kim, Hwanseok Rhee, Se Hoon Kim, Dong Hwan Shin, Kyung Young Chung, Kang-Sik Park, Young-Ki Paik, Joon Chang, Hoguen Kim.   

Abstract

The histopathologic type of lung cancer is known to be correlated with tumor behavior and prognosis. However, this classification is subjective and no specific molecular markers have been identified. The aim of this study was to identify protein markers in different types of nonsmall cell lung cancers. Two-dimensional polyacrylamide gel electrophoresis analysis was performed with paired samples of three squamous cell carcinomas, three adenocarcinomas, four large cell carcinomas, and four basaloid carcinomas. We found that 25 proteins in 14 cases of lung cancer were differentially expressed compared to matched nontumorous lung tissues. Among these 25 proteins, 11 proteins were down-regulated and 14 were up-regulated in these four types of lung cancer. Alloalbumin venezia, selenium-binding protein 1, carbonic dehydratase, heat shock 20KD-like protein, and SM22 alpha protein were down-regulated in all 14 cases of lung cancer examined, whereas alpha enolase was consistently up-regulated. Supervised hierarchical cluster analysis based on the 25 differentially expressed proteins showed that basaloid carcinoma formed one independent group, whereas the other three cancer types were not uniquely classifiable. Our findings suggest that basaloid carcinoma is a unique subtype of nonsmall cell lung carcinoma.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15378762     DOI: 10.1002/pmic.200400901

Source DB:  PubMed          Journal:  Proteomics        ISSN: 1615-9853            Impact factor:   3.984


  14 in total

Review 1.  Proteomic biomarkers in lung cancer.

Authors:  M D Pastor; A Nogal; S Molina-Pinelo; A Carnero; L Paz-Ares
Journal:  Clin Transl Oncol       Date:  2013-04-20       Impact factor: 3.405

2.  Proteomic profiling of follicular and papillary thyroid tumors.

Authors:  Anastasios Sofiadis; Susanne Becker; Ulf Hellman; Lina Hultin-Rosenberg; Andrii Dinets; Mykola Hulchiy; Jan Zedenius; Göran Wallin; Theodoros Foukakis; Anders Höög; Gert Auer; Janne Lehtiö; Catharina Larsson
Journal:  Eur J Endocrinol       Date:  2012-01-24       Impact factor: 6.664

Review 3.  From plasminogen to plasmin: role of plasminogen receptors in human cancer.

Authors:  Miroslava Didiasova; Lukasz Wujak; Malgorzata Wygrecka; Dariusz Zakrzewicz
Journal:  Int J Mol Sci       Date:  2014-11-17       Impact factor: 5.923

4.  Integrated analysis of mRNA, microRNA and protein in systemic lupus erythematosus-specific induced pluripotent stem cells from urine.

Authors:  Donge Tang; Yuyu Chen; Huiyan He; Jianrong Huang; Wenbiao Chen; Wujian Peng; Qianjin Lu; Yong Dai
Journal:  BMC Genomics       Date:  2016-07-11       Impact factor: 3.969

5.  Role of transgelin-2 in diabetes-associated pancreatic ductal adenocarcinoma.

Authors:  Yan Sun; Weiwei He; Man Luo; Yuhong Zhou; Guilin Chang; Weiying Ren; Kefen Wu; Xi Li; Jiping Shen; Xiaoping Zhao; Yu Hu
Journal:  Oncotarget       Date:  2017-07-25

Review 6.  Quantitative proteomics in lung cancer.

Authors:  Chantal Hoi Yin Cheung; Hsueh-Fen Juan
Journal:  J Biomed Sci       Date:  2017-06-14       Impact factor: 8.410

7.  Expression and clinicopathologic significance of TUFM and p53 for the normal-adenoma-carcinoma sequence in colorectal epithelia.

Authors:  Hong-Qing Xi; Ke-Cheng Zhang; Ji-Yang Li; Jian-Xin Cui; Po Zhao; Lin Chen
Journal:  World J Surg Oncol       Date:  2017-04-27       Impact factor: 2.754

8.  Reduced selenium-binding protein 1 in breast cancer correlates with poor survival and resistance to the anti-proliferative effects of selenium.

Authors:  Sheng Zhang; Feng Li; Mamoun Younes; Hao Liu; Changyi Chen; Qizhi Yao
Journal:  PLoS One       Date:  2013-05-21       Impact factor: 3.240

9.  Decreased selenium-binding protein 1 mRNA expression is associated with poor prognosis in renal cell carcinoma.

Authors:  Yun-Sok Ha; Geun Taek Lee; Ye-Hwan Kim; Se Yun Kwon; Seock Hwan Choi; Tae-Hwan Kim; Tae Gyun Kwon; Seok Joong Yun; Isaac Yi Kim; Wun-Jae Kim
Journal:  World J Surg Oncol       Date:  2014-09-16       Impact factor: 2.754

10.  Downregulation of SM22α protein by hypermethylation of its promoter in colorectal cancer.

Authors:  Yabin Liu; Erqiang Wei; Jian Zhao; Dexian Kong; Binghui Li
Journal:  Oncol Lett       Date:  2018-03-26       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.